SEPA Direct Debit B2B: Guidance for marketing authorisation holders and applicants

Human medicines European public assessment report (EPAR): SomaKit TOC, edotreotide, Date of authorisation: 08/12/2016, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Vyndaqel, tafamidis, Date of authorisation: 16/11/2011, Revision: 32, Status: Authorised

Tackling antimicrobial resistance: Information for animal health practitioners

Human medicines European public assessment report (EPAR): Bilprevda, denosumab, Date of authorisation: 17/09/2025, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Hulio, adalimumab, Date of authorisation: 17/09/2018, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Hemgenix, etranacogene dezaparvovec, Date of authorisation: 20/02/2023, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): mResvia, respiratory syncytial virus mRNA vaccine, Date of authorisation: 22/08/2024, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Voranigo, vorasidenib, Date of authorisation: 17/09/2025, Revision: 3, Status: Authorised

Paliperidone palmitate